Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT07583641RecruitingPhase 2
Testing Efgartigimod for Autoimmune Brain Inflammation
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
Tucson, ArizonaAges 12 years+ - NCT07118098Recruiting
Early detection of type 1 diabetes in families and friends
This study is for people ages 1 to 45 who have a close family member or friend with type 1 diabetes. It aims to detect type 1 diabetes early by screening people who may be at higher risk.
ViennaAges 1–45 - NCT04405700Recruiting
Tracking birth outcomes and birth defects after delivery
This study follows pregnant people and their babies to better measure adverse outcomes and possible congenital (from birth) conditions. It may help improve how birth risks and birth defects are identified and recorded at the clinic.
EldoretAges Any age - NCT07463521RecruitingPhase 3
Study of rozanolixizumab for ocular myasthenia gravis
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
Scottsdale, ArizonaAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT06087653RecruitingPhase 1/Phase 2
Continuous lenalidomide shot for multiple myeloma
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
Wilson, North CarolinaAges 18 years+ - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT07707739Recruiting
Plasma exchange for children with autoimmune encephalitis
This trial tests whether plasma exchange (a procedure that cleans the blood) can help children with a severe form of autoimmune encephalitis—a condition where the immune system attacks the brain. It's for children who haven't gotten better with standard treatments like steroids or IVIG.
Shibīn al Kawm, Menoufia GovernorateAges 1 month–18 years - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT05440422RecruitingPhase 2
Anifrolumab for heart and blood vessel health in lupus
This trial tests whether a drug called anifrolumab can improve early signs of heart and blood vessel damage in people with lupus. It may help prevent future heart problems and strokes.
Bethesda, MarylandAges 18–80 - NCT07774507Recruiting
Daily movement and artery health in rheumatoid arthritis
This study looks at how daily movement patterns (like sitting, standing, and walking) relate to the buildup of plaque in arteries (atherosclerosis) in people with rheumatoid arthritis. It aims to understand if certain activity levels can lower heart risks.
Presidente Prudente, São PauloAges 18–65 - NCT07777406Recruiting
Real-world study of donor stem cell transplant for relapsed/refractory myeloma
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
Chieti, CHAges 18 years+ - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT06645093Recruiting
Intermittent fasting during chemo for lymphoma
This study tests whether intermittent fasting is safe and doable for people with lymphoma who are getting standard chemotherapy (R-CHOP or ABVD). It aims to see if adding fasting periods can help reduce side effects.
Oslo, OsloAges 18–80 - NCT04910568RecruitingPhase 1
Study of cevostamab for people with returning or hard-to-treat myeloma
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
Los Angeles, CaliforniaAges 55 years+ - NCT07061574RecruitingPhase 1/Phase 2
Study of immune-modulating drugs for new-onset type 1 diabetes
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
San Francisco, CaliforniaAges 9–20 - NCT02479698RecruitingPhase 2
Immune cells for BK or JC virus infections
This trial tests a treatment using special immune cells (called cytotoxic T lymphocytes) to fight BK or JC virus infections in people with weakened immune systems, such as cancer patients or organ transplant recipients. It may help control the virus and reduce related complications.
Houston, TexasAges Any age - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT06575426RecruitingPhase 1/Phase 2
Pig pancreatic cell transplant for type 1 diabetes
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
Chicago, IllinoisAges 35–70 - NCT07779772Recruiting
Diet changes for children with eosinophilic gut disorders
This trial compares different elimination diets to see which one best reduces inflammation in children with eosinophilic gastrointestinal disorders. Your child might have fewer symptoms and a better outcome if the right diet is found.
Adana, SarıcamAges 2–18
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.